JPRN-jRCT2080220406未知2 期
An Open-Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-Menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer
适应症
试验速览
- 阶段
- 2 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Ages Eligible for Study: 18 Years and above
- •Genders Eligible for Study: Female
- •Inclusion Criteria:
- •- Pre-menopausal women aged 18 years or over with histologically/cytologically-confirmed oestrogen receptor positive (ER +ve) breast cancer.
- •- World Health Organization (WHO) performance status of 0, 1, or 2.
- •- Provided written informed consent.
排除标准
- •- Treatment with tamoxifen or other hormonal therapies as early breast cancer (EBC) adjuvant in the previous 24 weeks.
- •- Received radiotherapy within the past 4 weeks.
- •- History of systemic malignancy other than breast cancer within the previous 3 years.
- •- Estimated survival less than 24 weeks
研究者
相似试验
招募中
3 期
A large study in kids from birth to 18 years of age that have a documented clot in their lung or limbs, to test a new drug (edoxaban) used for treatment or the prevention of recurrent clots in your body.CTRI/2019/04/018361Daiichi Sankyo
未知
2 期
An Open-Label, Randomized, Parallel Group, Multicentre Study to Compare Oestradiol Suppression Between ZOLADEX 10.8 Mg Depot Given 3 Monthly and ZOLADEX 3.6 Mg Depot Given Monthly in Pre-Menopausal Patients With ER Positive Early Breast CancerBreast CancerJPRN-jRCT2080220258AstraZeneca
进行中（未招募）
不适用
An Open Label, Randomised, Parallel Group, Multicentre Study toCompare ZOLADEX™ 10.8 mg Given Every 12 Weeks with ZOLADEX3.6 mg Given Every 4 Weeks in Pre-menopausal Women with OestrogenReceptor Positive Advanced Breast CancerEUCTR2005-004001-29-CZAstraZeneca AB260
未知
3 期
An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast CancerBreast CancerJPRN-jRCT2080221070AstraZeneca
进行中（未招募）
1 期
A Randomized, Open-label, Parallel Group, Multicenter Pilot Study Evaluating the Efficacy and Safety of Alternative Dosing of Ribavirin vs. Standard of Care Dosing in Combination with Peginterferon alpha-2a in Interferon Naïve Patients with Chronic Hepatitis C Genotype 1 Infection - RibaCChronic hepatitis C infectionMedDRA version: 12.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2010-018332-41-DKDept. of Infectious diseases / virology University of Gothenburg105